SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

SELLAS Life Sciences (SLS) announced data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective ...

(RTTNews) - Sellas Life Sciences Group, Inc. (SLS), Wednesday announced positive data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective CDK9 inhibitor, ...

NSCLC治疗手段不断革新，一文为您解读！肺癌是全球范围内最常见的恶性肿瘤之一，其中非小细胞肺癌（NSCLC）约占肺癌病例的85%[1]。作为医学界的重点研究对象之一，NSCLC的治疗涉及多种手段，从手术到放射治疗，再到化疗、免疫治疗、靶向治疗，随着各种诊疗方法的不断进步，也为NSCLC患者的生存预后提供了更多可能性和机会。

According to the national cancer registration business annual report (2021 cancer registration statistics), the five-year ...